SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/05/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel Healthcare Conference 2013 on September 11, 2013, at 10:55 a.m. ET.
A live webcast of the presentation will be available under Webcasts in the Investors section of www.thresholdpharm.com. A replay of the presentation will be archived on the site for 30 days.
About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in the microenvironments of most solid tumors as well as the bone marrows of some patients with hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding the potential therapeutic uses and benefits of its product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to enroll or complete its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on August 1, 2013 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.
Laura Hansen, Ph.D.
Senior Director, Corporate Communications
|Aegerion Pharmaceuticals Announces Presentation at the Morgan Stanley Global Healthcare Conference (2013/9/5)|
|Alexza Pharmaceuticals to Present at the Stifel Healthcare Conference 2013 ()|
|AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013 (2013/8/30)|
|Conatus Pharmaceuticals to Present at Stifel Healthcare Conference 2013 (2013/9/4)|
|VCA Antech, Inc. to Present at Stifel Healthcare Conference 2013 ()|
|Chimerix to Present at Morgan Stanley and Stifel Healthcare Conferences in September (2013/9/6)|
|KaloBios to Present at Stifel Healthcare Conference 2013 (2013/9/5)|
|MEDNAX to Present at the Stifel Healthcare Conference 2013 in Boston (2013/9/5)|
|Novadaq to Present at the Stifel Healthcare Conference 2013 ()|
|Repligen to Present at the Stifel Healthcare Conference 2013 (2013/9/4)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.